Table 1.

Demographic characteristics of REDUCE participants according to the presence of chronic and acute prostate inflammation at baseline

Chronic prostate inflammationAcute prostate inflammation
Absent N = 1,504 (23%)Present N = 5,151 (77%)PAbsent N = 5,650 (85%)Present N = 1,005 (15%)P
Age, mean (SD), y62.2 (6.1)62.8 (6.0)0.000662.8 (6.0)62.1 (6.1)0.0002
Race, n (%)
 White1,400 (93)4,698 (91)0.0215,177 (92)921 (92)0.989
 Non-white104 (7)453 (9)473 (8)84 (8)
Region, n (%)
 North America336 (22)1,562 (30)<0.00011,496 (26)402 (40)<0.0001
 Europe990 (66)2,947 (57)3,405 (60)532 (53)
 Other178 (12)642 (12)749 (13)71 (7)
BMI, median (IQR), kg/m226.8 (24.8–29.0)26.9 (24.9–29.4)0.27726.9 (24.9–29.4)26.9 (24.8–29.3)0.766
Diabetes, n (%)
 No1,369 (91)4,726 (92)0.3735,174 (92)921 (92)0.944
 Yes135 (9)425 (8)476 (8)84 (8)
Statin use, n (%)
 No1,212 (81)4,226 (82)0.1984,632 (82)806 (80)0.178
 Yes292 (19)925 (18)1,018 (18)199 (20)
NSAID use, n (%)
 No1,075 (71)3,629 (70)0.4434,011 (71)693 (69)0.191
 Yes429 (29)1,522 (30)1,639 (29)312 (31)
Alcohol use, n (%)a
 None360 (24)1,372 (27)0.0401,472 (26)260 (26)0.693
 Moderate720 (48)2,463 (48)2,692 (48)491 (49)
 Heavy417 (28)1,292 (25)1,461 (26)248 (25)
Smoking status, n (%)
 Never698 (46)2,321 (45)0.1242,580 (46)439 (44)0.001
 Former604 (40)2,028 (39)2,257 (40)375 (37)
 Current202 (13)802 (16)813 (14)191 (19)
  • Abbreviation: IQR, interquartile range.

  • aData for alcohol use was missing for n = 31 participants.